Safety of Conversion From Twice-Daily Tacrolimus (Prograf) to Once-Daily Prolonged-Release Tacrolimus (Advagraf) in Stable Liver Transplant RecipientsCOMUZZI, C; LORENZIN, D; ADANI, G. L et al.Transplantation proceedings. 2010, Vol 42, Num 4, pp 1320-1321, issn 0041-1345, 2 p.Conference Paper

Kinetics of serum soluble tumour necrosis factor receptor (TNF-R) type-I and type-II after a single interferon-alpha (IFN-α) injection in chronic hepatitis CFABRIS, C; DEL FORNO, M; FALLETI, E et al.Clinical and experimental immunology (Print). 1999, Vol 117, Num 3, pp 556-560, issn 0009-9104Article

High prevalence of infection with hepatitis G virus in patients with hepatic and extrahepatic malignanciesTONIUTTO, P; PIRISI, M; BARTOLI, E et al.Journal of hepatology. 1998, Vol 28, Num 4, pp 550-555, issn 0168-8278Article

Sorafenib: from literature to clinical practiceDI MARCO, V; DE VITA, F; KOSKINAS, J et al.Annals of oncology. 2013, Vol 24, issn 0923-7534, ii30-ii37, SUP2Article

Long-Term Outcomes of Orthotopic Liver Transplantation in Human Immunodeficiency Virus-Infected Patients and Comparison With Human Immunodeficiency Virus-Negative CasesBACCARANI, U; ADANI, G. L; TONIUTTO, P et al.Transplantation proceedings. 2011, Vol 43, Num 4, pp 1119-1122, issn 0041-1345, 4 p.Conference Paper

Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseasesPIRISI, M; FABRIS, C; FALLETI, E et al.Disease markers. 1996, Vol 13, Num 1, pp 11-17, issn 0278-0240Article

Evidence for a multifactorial control of serum erythropoietin concentration in liver diseasePIRISI, M; FABRIS, C; FALLETI, E et al.Clinica chimica acta. 1993, Vol 219, Num 1-2, pp 47-55, issn 0009-8981Article

De Novo Tumors Are a Major Cause of Late Mortality After Orthotopic Liver TransplantationBACCARANI, U; ADANI, G. L; BRESADOLA, V et al.Transplantation proceedings. 2009, Vol 41, Num 4, pp 1303-1305, issn 0041-1345, 3 p.Conference Paper

Steatosis of the Graft Is a Risk Factor for Posttransplantation Biliary ComplicationsBACCARANI, U; ADANI, G. L; BRESADOLA, V et al.Transplantation proceedings. 2009, Vol 41, Num 4, pp 1313-1315, issn 0041-1345, 3 p.Conference Paper

A study on the role of the family and other risk factors in HCV transmissionBRUSAFERRO, S; BARBONE, F; FERRONI, P et al.European journal of epidemiology. 1999, Vol 15, Num 2, pp 125-132, issn 0393-2990Article

Endogenous interferon-α concentration and outcome of interferon treatment in patients with chronic hepatitis CPIRISI, M; FABRIS, C; BARTOLI, E et al.Digestive diseases and sciences. 1997, Vol 42, Num 4, pp 767-771, issn 0163-2116Article

Discordant results from hepatitis C virus genotyping by procedures based on amplification of different genomic regionsTONIUTTO, P; PIRISI, M; BARALLE, F et al.Journal of clinical microbiology (Print). 1996, Vol 34, Num 10, pp 2382-2385, issn 0095-1137Article

Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patientsPIRISI, M; TONIUTTO, P; UZZAU, A et al.Cancer. 2000, Vol 89, Num 2, pp 297-302, issn 0008-543XConference Paper

IgM antibody response to the hepatitis C virus core protein in intravenous drug usersTONIUTTO, P; FALLETI, E; GASPARINI, V et al.Diagnostic microbiology and infectious disease. 1999, Vol 33, Num 2, pp 69-73, issn 0732-8893Article

A comparison of four serum markers of fibrosis in the diagnosis of cirrhosisFABRIS, C; FALLETI, E; FEDERICO, E et al.Annals of clinical biochemistry. 1997, Vol 34, pp 151-155, issn 0004-5632, 2Article

Anti-envelope antibodies in anti-hepatitis C virus (HCV) positive patients with and without liver diseasePIRISI, M; FERRONI, P; FABRIS, C et al.Infection. 1995, Vol 23, Num 1, pp 24-28, issn 0300-8126Article

Thrombocytopenia of chronic liver disease corrected by erythropoietin treatmentPIRISI, M; FABRIS, C; SOARDO, G et al.Journal of hepatology. 1994, Vol 21, Num 3, pp 376-380, issn 0168-8278Article

Intensity of inflammatory damage and serum lipid peroxide concentrations in liver diseaseFABRIS, C; PIRISI, M; PANOZZO, M. P et al.Journal of clinical pathology. 1993, Vol 46, Num 4, pp 364-367, issn 0021-9746Article

Factors associated with serum HCV RNA positivity in anti-HCV antibody positive intravenous drug usersPIRISI, M; TONIUTTO, P; FABRIS, C et al.Journal of clinical epidemiology. 1998, Vol 51, Num 5, pp 423-427, issn 0895-4356Article

Diagnostic usefulness of acute-phase protein measurement in hepatocellular carcinomaFABRIS, C; PIRISI, M; SOARDO, G et al.Cancer investigation. 1996, Vol 14, Num 2, pp 103-108, issn 0735-7907Article

Circulating intercellular adhesion molecule 1 predicts non-specific elevation of α1-fetoproteinFALLETI, E; FABRIS, C; PIRISI, M et al.Journal of cancer research and clinical oncology. 1996, Vol 122, Num 6, pp 366-369, issn 0171-5216Article

Hepatic release of erythropoietin induced by transarterial chemoembolization in patients with hepatocellular carcinomaPIRISI, M; FABRIS, C; SOARDO, G et al.Hepatology (Baltimore, Md.). 1995, Vol 22, Num 1, pp 148-152, issn 0270-9139Article

Reactivity to B cell epitopes within hepatitis C virus core protein and hepatocellular carcinomaPIRISI, M; FABRIS, C; TONIUTTO, P et al.Cancer research (Baltimore). 1995, Vol 55, Num 1, pp 111-114, issn 0008-5472Article

Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosisFABRIS, C; PIRISI, M; SOARDO, G et al.Journal of cancer research and clinical oncology. 1994, Vol 120, Num 4, pp 229-232, issn 0171-5216Article

Increase of serum α₁-acid glycoprotein despite the decline of liver synthetic function in cirrhotics with hepatocellular carcinomaFALLETI, E; PIRISI, M; FABRIS, C et al.European journal of clinical chemistry and clinical biochemistry. 1993, Vol 31, Num 7, pp 407-411, issn 0939-4974Article